- Home
- PYPD vs CMMB Comparison
PYPD vs CMMB Comparison
Compare PYPD & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- CMMB
- Stock Information
- Founded
- PYPD 2008
- CMMB 2004
- Country
- PYPD Israel
- CMMB Israel
- Employees
- PYPD N/A
- CMMB N/A
- Industry
- PYPD Medical/Dental Instruments
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- CMMB Health Care
- Exchange
- PYPD Nasdaq
- CMMB Nasdaq
- Market Cap
- PYPD 16.3M
- CMMB 15.8M
- IPO Year
- PYPD 2020
- CMMB N/A
- Fundamental
- Price
- PYPD $3.54
- CMMB $1.36
- Analyst Decision
- PYPD Buy
- CMMB Strong Buy
- Analyst Count
- PYPD 2
- CMMB 3
- Target Price
- PYPD $12.00
- CMMB $5.67
- AVG Volume (30 Days)
- PYPD 4.8K
- CMMB 209.5K
- Earning Date
- PYPD 11-06-2024
- CMMB 11-07-2024
- Dividend Yield
- PYPD N/A
- CMMB N/A
- EPS Growth
- PYPD N/A
- CMMB N/A
- EPS
- PYPD N/A
- CMMB N/A
- Revenue
- PYPD N/A
- CMMB N/A
- Revenue This Year
- PYPD N/A
- CMMB N/A
- Revenue Next Year
- PYPD N/A
- CMMB N/A
- P/E Ratio
- PYPD N/A
- CMMB N/A
- Revenue Growth
- PYPD N/A
- CMMB N/A
- 52 Week Low
- PYPD $2.95
- CMMB $0.42
- 52 Week High
- PYPD $9.20
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- PYPD 50.62
- CMMB 36.25
- Support Level
- PYPD $3.31
- CMMB $1.29
- Resistance Level
- PYPD $3.62
- CMMB $1.59
- Average True Range (ATR)
- PYPD 0.19
- CMMB 0.17
- MACD
- PYPD 0.01
- CMMB -0.04
- Stochastic Oscillator
- PYPD 51.22
- CMMB 12.95
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.